ERBB2 and breast carcinoma: It is well known that estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) contribute to breast cancer progression, and ER- and PR-positive breast cancer patients usually receive endocrine treatment [27].